Clinical Trial

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Study acronym: COFRUQ
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2026-05-22
Trial Details
NCT Number NCT07124858
Lead Sponsor Federation Francophone de Cancerologie Digestive
Conditions Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI
Enrollment 300 participants
Start Date 2026-03-10
Primary Completion 2031-03-01 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26